Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia
Severely afflicted patients with the COVID-19 may become in need of mechanical ventilation. The cause of acute respiratory failure is a massive hyperinflammation in the lungs, and treatment with glucocorticoids is not recommended by the WHO. A rare haematological disease, the virus-associated haemophagocytic lymphohistiocytosis syndrome (HLS), is associated with high mortality and a similar hyperinflammation syndrome. Janus kinase (JAK) 1/2 inhibitor treatment is highly efficacious in HLS. In this review, we discuss the rationales and perspectives for using JAK1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:182 |
|---|---|
| Enthalten in: |
Ugeskrift for laeger - 182(2020), 25 vom: 15. Juni |
| Sprache: |
Dänisch |
|---|
| Beteiligte Personen: |
Hasselbalch, Hans Carl [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 14.07.2020 Date Revised 18.12.2020 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM311630995 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311630995 | ||
| 003 | DE-627 | ||
| 005 | 20231225142649.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||dan c | ||
| 028 | 5 | 2 | |a pubmed24n1038.xml |
| 035 | |a (DE-627)NLM311630995 | ||
| 035 | |a (NLM)32584762 | ||
| 035 | |a (PII)V04200234 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dan | ||
| 100 | 1 | |a Hasselbalch, Hans Carl |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.07.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Severely afflicted patients with the COVID-19 may become in need of mechanical ventilation. The cause of acute respiratory failure is a massive hyperinflammation in the lungs, and treatment with glucocorticoids is not recommended by the WHO. A rare haematological disease, the virus-associated haemophagocytic lymphohistiocytosis syndrome (HLS), is associated with high mortality and a similar hyperinflammation syndrome. Janus kinase (JAK) 1/2 inhibitor treatment is highly efficacious in HLS. In this review, we discuss the rationales and perspectives for using JAK1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Janus Kinase Inhibitors |2 NLM | |
| 700 | 1 | |a Poulsen, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Skov, Vibe |e verfasserin |4 aut | |
| 700 | 1 | |a Kjær, Lasse |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, Claus Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Poulsen, Troesl Dirch |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ugeskrift for laeger |d 1945 |g 182(2020), 25 vom: 15. Juni |w (DE-627)NLM000011185 |x 1603-6824 |7 nnns |
| 773 | 1 | 8 | |g volume:182 |g year:2020 |g number:25 |g day:15 |g month:06 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 182 |j 2020 |e 25 |b 15 |c 06 | ||